Hepatitis C virus (HCV) is a significant public health problem. Approximately 3% of the world's population has persistent HCV infection. 1 In 1989, the virus was identified as the major aetiological agent responsible for post-transfusion non-A and non-B hepatitis. [2] [3] [4] [5] [6] Following primary HCV infection, persistent viraemia and chronic hepatitis develop in the majority of cases.
Hepatitis C virus (HCV) is a significant public health problem. Approximately 3% of the world's population has persistent HCV infection. 1 In 1989, the virus was identified as the major aetiological agent responsible for post-transfusion non-A and non-B hepatitis. [2] [3] [4] [5] [6] Following primary HCV infection, persistent viraemia and chronic hepatitis develop in the majority of cases. 7 Patients are at risk of progressive hepatic fibrosis, cirrhosis and death from liver failure, as well as the advent of hepatocellular carcinoma. 8 Efforts to elucidate the mechanisms behind viral persistence and hepatocellular damage have been frustrated by the lack of a reliable cell culture system for viral propagation in vitro. In addition, as the chimpanzee is the only experimental animal susceptible to HCV infection, progress in research is hampered by the lack of a small animal model to facilitate pathophysiological studies as well as the evaluation of antiviral treatment and vaccine strategies.
The epidemiology and clinical aspects of HCV infection are briefly outlined below, followed by a summary of aspects of the molecular virology of HCV. The review of immunity in HCV infection focuses on: (i) the role of viral diversity in immune evasion, and other potential mechanisms of HCV persistence; (ii) the contribution of immune responses to hepatocellular injury; (iii) studies investigating potential components of protective immunity against HCV, notably HCV-specific cytotoxic T lymphocytes (CTL); and (iv) the unique immunological environment encountered in the liver. The pathogenesis of HCV-related fibrosis, hepatocellular carcinoma and autoimmune disease associated with HCV infection are not discussed in detail. Potential insights into the immunopathogenesis of HCV infection may be gained by considering the immune response to other members of the Flaviviridae family, and to the hepatitis B virus (HBV), another viral agent responsible for chronic liver disease.
Hepatitis C is an hepatotropic flavivirus
Hepatitis C virus was cloned from the plasma of an experimentally infected chimpanzee and characterized as a positive sense, ssRNA virus. 2 On the basis of genome homology and hydrophobicity patterns, which are similar to the pestiviruses and flaviviruses, HCV has been classified as the first member of a third genus called Hepacivirus within the family Flaviviridae. 9, 10 Pestiviruses, such as bovine viral diarrhoea virusSimilar to HCV, HBV is an hepatotropic virus that can cause persistent infection, chronic hepatitis, cirrhosis and hepatocellular carcinoma. 13 Hepatitis B virus is a noncytopathic virus with a small, circular dsDNA genome and a lipoprotein envelope. 14 In contrast to HCV, 95% of adults with primary HBV infection experience a self-limited illness that is attributed to an effective immune response and viral clearance. 15 Vaccination with hepatitis B surface antigen results in the generation of protective antibody and a longlived anamnestic response in the majority of cases. 16 
Hepatitis C is a common pathogen
Hepatitis C infection has been documented in sera stored in the 1950s. 17 To the end of 1997, 190 000 Australians (i.e. approximately 1% of the population) were estimated to have antibodies to HCV and the annual incidence of new infections was estimated at 11 000. 18 In the United States approximately 2.7 million persons suffer from persistent HCV infection. 19 The prevalence is considerably higher in developing countries, such as parts of Africa and the Middle East. 20, 21 Hepatitis C virus represents a major economic burden to the health-care system because of the substantial medical costs incurred in managing patients with persistent infection. 22, 23 Hepatitis C is spread through blood-to-blood exposure Hepatitis C virus transmission occurs principally through parenteral exposure to contaminated blood or blood products. 24 Because of the introduction of blood product and organ donor screening (in 1990 in Australia) the main risk factor for HCV infection remains injecting drug use. 25, 26 Between 50% and 70% of Australian injecting drug users are infected with HCV. 18, 27, 28 Other risk factors for HCV infection include acupuncture, tattooing, haemodialysis, occupational exposure in health-care workers, and the re-use of needles in mass vaccination programs. 24, 29 The rate of transmission from mother-to-infant is approximately 6%. 30 The majority of vertical HCV transmission occurs at the time of delivery. 31 Early studies suggest that transmission is more common in the setting of high maternal viral load or in the presence of concomitant HIV infection. [32] [33] [34] However, a recent study demonstrated that the viral load was the same in transmitting and non-transmitting women, and that vertical transmission was associated with the presence of negativestrand intermediates in maternal peripheral blood mononuclear cells. 35 This supports the hypothesis that the transfer of infected cells to the infant is the major cause of vertical HCV transmission. Breast-feeding is not thought to increase infection risk to babies. 31 Hepatitis C virus is not found consistently in bodily secretions, thus sexual transmission is rare. 36, 37 A small proportion of patients with no identifiable risk factor for HCV hepatitis are designated as sporadic cases and presumably reflect unrecognized or unreported blood-to-blood exposure. The majority of flaviviruses are transmitted to vertebrates by infected arthropods. 9 However, mosquitoes fed HCV-infected blood are only transiently positive for viral RNA and are, therefore, incompetent as a vector of HCV.
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The liver in chronic hepatitis C contains a lymphocytic infiltrate and develops progressive fibrosis
The histological features of persistent HCV infection are those of chronic hepatitis, with expanded portal tracts and lobular inflammation of varying severity. 39, 40 The infiltrate contains predominantly CD8 + T cells (Fig. 1) . 41 Lymphocytes may form focal aggregates that occasionally take the form of follicles with germinal centres. The limiting plates of hepatocytes around portal tracts may be eroded by interface hepatitis, also known as piecemeal necrosis. In contrast to chronic hepatitis B, confluent 'bridging' necrosis is uncommon. Hepatocytes in chronic HCV hepatitis may show acidophilic degeneration within intact plates and form apoptotic (Councilman) bodies. Bile duct damage and proliferation may also occur. Microvesicular fat accumulation (steatosis) is common, but rarely severe. Iron deposition (siderosis) is also rarely severe. However, in patients with thalassaemia major who receive multiple blood transfusions, or those with the inherited iron storage disorder, haemochromatosis, HCV can act synergistically with iron to promote liver damage. 42 Progressive fibrosis occurs in patients with persistent HCV infection with a generally increasing prevalence over decades of chronic hepatitis. 43 Once cirrhosis has developed the histological changes are less characteristic.
Liver biopsies in patients with chronic HCV hepatitis are generally evaluated in terms of grade and stage. Grading is used to describe the intensity of necro-inflammatory activity. Staging is a measure of the fibrosis and architectural distortion that are the precursors of cirrhosis. A numerical score, for example the Knodell score with modifications by Ishak, 44, 45 is commonly assigned to both grade and stage, thereby providing a semiquantitative assessment of the observed histological features.
Primary hepatitis C virus infection results in persistent infection and cirrhosis in a significant proportion of cases
Primary HCV infection is predominantly asymptomatic and fulminant hepatic failure in this context is rare. 46, 47 Serum HCV RNA can be identified by PCR as early as 7-21 days after exposure. 48, 49 There is a decline in the level of viraemia around the time of initial alteration in biochemical tests of liver function, notably a rise in the level of serum transaminases. 49 Seroconversion typically occurs after approximately 2-8 weeks. 50 Patients who present with jaundice (thus indicating more severe liver injury) during primary infection are more likely to clear HCV than the majority who acquire HCV without apparent symptoms. [51] [52] [53] [54] [55] Some estimates suggest that persistent infection develops in approximately 80% of cases of HCV. 54, 56, 57 However, considering that primary infection is predominantly asymptomatic and that antibody disappears in the intermediate term in a proportion of those who clear the virus, 58 the true figure may be closer to 50%. The majority of patients with persistent HCV will have ongoing biochemical and histological evidence of hepatitis, but are typically either asymptomatic or have only mild fatigue. 47 The most readily available marker of liver injury, the serum transaminase levels, characteristically fluctuate widely over time, correlate poorly with histological disease activity and may be normal in patients with severe hepatitis and cirrhosis. [59] [60] [61] The major morbidity and mortality of persistent HCV infection occurs after the establishment of hepatic fibrosis and the subsequent occurrence of cirrhosis and hepatocellular carcinoma. 8 In those patients who develop clinically apparent HCV-related liver disease, the evolution is typically very slow with an average time to presentation with chronic hepatitis, cirrhosis and hepatocellular carcinoma of approximately 10, 20 and 30 years, respectively. 62 As the infection is typically asymptomatic in the majority of patients, and runs a protracted course, it has been difficult to define the true proportion of cases that will progress to cirrhosis. 63 There have been a large number of published series of patients recruited through specialist clinics that report an HCV-related cirrhosis rate in excess of 30% after 20 years infection. 64, 65 These cross-sectional series of referred patients, while containing large numbers of subjects, give a distorted picture of the natural history of HCV infection due to a selection bias towards patients with more severe disease. Data from population-based cohorts suggest that less than 10% of patients with persistent HCV infection, acquired in young adulthood, will progress to cirrhosis after 20 years infection. 66 The situation in the third and fourth decades is less certain, however, there is evidence that the rate of progression of hepatic fibrosis beyond 20 years is linear. 43 Consistent with this impression of a more favourable outcome, a recent 45 year follow up of 17 American male military recruits with persistent HCV infection demonstrated that only 2 (12%) had developed advanced liver disease. 17 Factors shown to accelerate progression to cirrhosis in persistent HCV infection include older age at HCV infection, male gender, heavy alcohol intake and co-infection with either HBV or HIV. 43, [67] [68] [69] The annual incidence of hepatocellular carcinoma is approximately 3% among HCV positive patients with cirrhosis. 70 With regard to mortality, subjects with posttransfusion HCV infection followed-up 25 years after acquiring HCV during open-heart surgery had no excess all-cause mortality and only a small increase in liver-related mortality compared with age-matched controls. 71, 72 The mortality attributable to community acquired HCV infection as a result of injecting drug use remains to be defined.
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Current therapies for hepatitis C are only partially effective
The goal of treatment is to eradicate HCV and prevent progression of liver disease. The two drugs currently available are IFN-α, a cytokine with immunomodulatory and antiviral activity, and ribavirin, a synthetic guanosine nucleoside analogue with in vitro antiviral activity. 74 After a 48-week course of parenteral IFN-α monotherapy, less than 20% of patients with persistent HCV infection will clear the virus and show a sustained normalization of serum transaminase levels. 75, 76 A four-year follow up of treatment responders suggests that patients with persistently undetectable HCV RNA are cured. 77 Ribavirin monotherapy has been shown to transiently decrease serum transaminase concentrations, but has no effect on serum viral load. 78 Combination therapy with IFN-α and ribavirin, however, increases sustained virological and biochemical response rates to between 40% and 50%. 79, 80 Patients with higher serum HCV RNA levels, severe hepatic fibrosis and significant siderosis, and men, are less likely to respond to treatment. 76, 81 Hepatitis C virus has become the commonest indication for liver transplantation in Australia and worldwide. 82, 83 Chronic hepatitis redevelops in the majority of transplant recipients, but rarely leads to severe fibrosis or graft failure within the first decade.
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Much remains to be learnt about the molecular virology of hepatitis C The RNA genome of HCV consists of a single uninterrupted open-reading frame, approximately 9400 nucleotides in length, bracketed by 5′-and 3′-non-coding regions. 85, 86 Protein translation begins at an internal ribosomal entry site (IRES) in the 5′-non-coding region. 87 The full-length polyprotein of approximately 3000 amino acids undergoes post-translational cleavage by host and viral proteases into HCV core, envelope glycoproteins (E1, E2) and nonstructural proteins (NS2, NS3, NS4A/B, NS5A/B) (Fig. 2) . 88 The core protein is thought to interact with RNA to form the virion nucleocapsid, 89 while the non-structural regions are likely to have a role in virus replication and encode for proteases (NS2, NS3), a helicase (NS3) and an RNA-dependant RNA polymerase (NS5B). 90 The virion half-life is between 3 and 5 h, with a clearance and production rate of approximately 10 12 particles per day, corresponding to 50 particles per infected hepatocyte per day. 91 Similar to other Flaviviridae, HCV is a small spherical virus (diameter approximately 30-50 nm) 92, 93 with a lipophilic envelope. 94 Hepatitis C virus has been shown to associate with low density lipoproteins (LDL) in human sera. 95, 96 It has been proposed that an interaction between HCV-LDL complexes with LDL receptor is responsible for HCV binding and cell entry. [97] [98] [99] However, the specific mechanism by which HCV particles interact with LDL receptor prior to internalization remains unclear. In addition, HCV E2 protein has been shown to bind the major extracellular loop of human CD81, a cell surface molecule expressed on virtually all nucleated cells. 100 However, recent evidence suggests that this interaction is not important for HCV entry into cells. 99, 101, 102 Hepatitis C virus envelope proteins may be important for fusion with the endosomal membrane through binding alternative, unidentified, cell surface proteins.
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Diagnosis of hepatitis C is based on serology and detection of viral RNA by PCR Serological assays for diagnosis of HCV were initially based on the detection of circulating antibody reactive to C100-3, a recombinant epitope derived from NS4. 3 These assays lacked sensitivity and specificity, particularly in samples collected early in the course of HCV infection. 104 Subsequent second and third generation enzyme-linked immunoassays and recombinant immunoblot assays detect circulating antibodies to multiple HCV epitopes, including core, which have been shown to appear earlier in the illness. 105 Consequently, serological diagnosis has a sensitivity and specificity that approaches 95% when compared with serum HCV RNA detection by PCR of reverse transcribed cDNA. 106 There is however, a proportion of HCV-infected individuals who are HCV RNA positive, but negative by serology. 107 This group
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Figure 2 Schematic diagram of the hepatitis C virus (HCV) genome. The location of HCV genes (C, core; E1/2, envelope; NS2/3/4A/4B/5A/5B, non-structural), proposed functions of gene products, and the 5′ and 3′ untranslated regions (5′UTR and 3′XR) are shown. Numbering refers to nucleotide positions of genes. From: Liang et al. 352 includes a small group of patients who have a delay of over 12 months before seroconversion after primary infection. 108 Despite this, because serum HCV RNA levels fluctuate significantly over time and may give a false-negative result if the rate of viral replication is low or if viral persistence is limited to the liver, PCR testing is generally used to confirm persistent HCV infection only following serological testing for anti-HCV antibodies.
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The liver is the principal site of hepatitis C replication Immunohistochemical studies of liver specimens from patients with persistent HCV infection have demonstrated structural and non-structural antigens located almost exclusively within the cytoplasm of hepatocytes. 110 In situ hybridization to detect complementary negative-strand RNA confirms that hepatocytes are the primary target for intrahepatic HCV replication. 111, 112 Early reports suggested that only a small proportion of hepatocytes are positive for negative-strand RNA, however, more recent evidence suggests that 25%, 113 or even up to 73%, 114 of these cells may have replicating HCV within them. The potential for extrahepatic replication and the biological significance of negative-strand RNA intermediates in both liver-infiltrating mononuclear cells and PBMC is unresolved. [115] [116] [117] [118] [119] [120] [121] [122] [123] Additional sites of apparent extra-hepatic replication in immunodeficient hosts include lymph nodes, spleen, pancreas, adrenal gland and thyroid.
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Hepatitis C has a highly variable genome
The genomic sequences of individual HCV isolates vary by as much as 35%. This nucleotide sequence heterogenicity is unevenly distributed over the genome. The most highly conserved region is at the terminus of the 5′-non-coding region. 125 The proximal 3′-non-coding region varies in nucleotide sequence and length, downstream of which most isolates have a poly(U) stretch followed by a highly conserved 98-nucleotide tail. 126 The conserved non-coding sequences are believed to be important for regulation of viral replication and gene expression. 127 The putative core is the most highly conserved HCV protein, followed by conserved sequences in NS3 and NS5. 128 The envelope proteins contain conserved elements, but overall these proteins are highly variable. A domain of approximately 28 amino acids at the amino-terminal end of E2 is so diverse among different HCV isolates that it has been labelled the hypervariable region (HVR1). 129 However, despite significant variation at the nucleotide level, it retains a conformational structure that suggests it is involved in interactions with negatively charged compounds such as glycosaminoglycans and phospholipids. 130 This is consistent with the hypothesis that HVR1 is important in interactions between HCV and the cell surface.
Hepatitis C exists as a dynamic quasispecies
Typically, RNA viruses show high mutation frequencies because of an error-prone viral RNA polymerase that lacks proof-reading 3′-5′ exonuclease activity. 131 For HCV, the rate of nucleotide misincorporation has been calculated as approximately 10 -3 base substitutions per genome site per year. 132, 133 The resulting genetic diversity defines the evolution of a quasispecies: a complex population of closely related HCV variants circulating simultaneously in each individual patient. 134 The quasispecies encompasses a predominant 'master' genome, which is believed to have a superior replicative capacity, and a multitude of distinct 'minor' genomes. Generally, HCV quasispecies vary by less than 5% in nucleotide sequence. 135 The generation and evolution of the quasispecies is likely to have important implications for escape from immune surveillance, generation of drug resistance and vaccine failure. 136 Considering the potential role of the HVR1 in cell entry, as discussed above, and its high rate of nucleotide diversity, it is conceivable that different components of the quasispecies within a single patient may display different cellular tropism. This may explain the observation that circulating quasispecies do not always reflect those of the intrahepatic virus.
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The six hepatitis C genotypes may vary in pathogenicity Phylogenetic analysis of HCV isolates worldwide has lead to the classification of HCV variants into six 1-6 distinct genotypes based on the NS5 region. 139 Hepatitis C virus genotypes vary by as much as 30% in nucleotide sequence. 135 Multiple, closely related isolates within these six genetic groups have been identified and are classified into subtypes (for example, 1a, 1b). It is not yet resolved as to whether more recently identified isolates from South-East Asia should be classified within the established six genotypes or represent three distinct, additional genetic variants. [140] [141] [142] Detection of viral nucleotide sequence variations can be achieved using polymerase chain reaction (PCR) sequencing, type-specific primers, heteroduplex mobility analysis, selective hybridization and restriction fragment length polymorphism techniques targeting well-conserved areas, typically the 5′-non-coding region, of the HCV genome. 143 Alternatively, serological methods that rely on differential detection of antibodies to antigenic sites, for example NS4, can be used to type HCV isolates. 144 Genotype-specific changes in one region of the genome predict changes in other areas, thus, detection of type-specific antibody to NS4 peptides has been shown to correspond with PCR-based genotyping in almost all cases. 145, 146 The prevalent HCV genotypes vary in different geographical regions. Genotype 1 is widely distributed; however, in the United States genotype 1a predominates, while in Japan type 1b and 2a are most common. Genotype 4 is essentially restricted to the Middle East and central Africa, genotype 5 to South Africa and genotype 6 to Hong Kong. 20, 21, 147, 148 The distribution of given genotypes can vary in a single area over time. Over the past 30 years in Australia there has been an emergence of genotype 3, which is endemic in South-East Asia and India, and a corresponding relative reduction in the prevalence of genotype 1. 149, 150 All currently recognized HCV genotypes are hepatotropic and pathogenic. 151 However, it has been suggested that different genotypes do vary in their infectivity and pathogenicity, thereby influencing the rate of progression to cirrhosis and the risk of hepatocellular carcinoma. 152, 153 Specifically, genotype 1b has been reported to be associated with higher HCV RNA levels, more advanced disease and a poor response to treatment. [154] [155] [156] [157] [158] [159] However, this has not been a universal finding. [160] [161] [162] [163] [164] The association between type 1b infection and a worse prognosis may be confounded by factors such as acquisition of HCV through blood transfusion, an older age at infection and a longer duration of disease.
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Hepatitis C persists despite a vigorous immune response
In contrast to other flavivirus infections and HBV, the majority of adults with primary HCV infection develop persistent infection. In addition, HCV can be responsible for multiple episodes of acute disease in an individual. Repetitive exposure of chimpanzees to heterologous and homologous HCV strains results in the reappearance of viraemia, as well as histopathological evidence of acute hepatitis attributable to reinfection rather than reactivation of the original strain. 168, 169 Similar observations have been made in multiply transfused thalassaemic children. 170 As a DNA replicative intermediate has never been demonstrated in the HCV life cycle, there is no evidence to suggest that persistent HCV infection is related to viral integration into the host genome. Persistence must, therefore, relate to the inability of the host to mount an effective immune response, to viral factors that facilitate immune evasion, or to a combination of these factors.
There is no evidence to suggest that individuals with persistent HCV infection are globally immunosuppressed. 171, 172 There is, in fact, considerable evidence that the majority of HCV-infected patients are capable of mounting polyclonal cellular and humoral immune responses directed at both structural and non-structural viral proteins. The recognized components of the adaptive anti-HCV immune response are summarized in Figure 3 and are discussed below.
Immune responses may mediate liver injury in hepatitis C
In persistent HCV infection the immune response may contribute to hepatocellular injury. Immunosuppression of patients is generally associated with a transient normalization of serum transaminase levels and a surge in viraemia, while removal of immunosuppression can lead to an acute exacerbation of hepatitis. 173 In addition, immunohistochemical studies in HCV infection indicate that T lymphocytes predominate both in the expanded portal tracts and inflammatory lobular infiltrates, suggesting that these cells are important mediators of HCV-related liver disease. 41 The mechanisms of accumulation of effector cells in the liver in the setting of HCV are largely unexplored. The T-cell chemoattractant, interferon-inducible protein 10 (IP-10) is strongly expressed in HCV-infected liver. 174, 175 Our recent studies have demonstrated that hepatocytes are the major source of this chemokine, and that levels correlate with the degree of lobular inflammation. by measuring PBMC proliferation in vitro in response to recombinant HCV proteins, have revealed that between 50% and 75% of individuals with persistent HCV infection have CD4 + T-cell responses to core, NS3, NS4 or NS5 proteins. [179] [180] [181] [182] A hierarchy of T-cell responsiveness to HCV proteins has been defined with core being the most immunogenic followed by NS4. 183, 184 Rather than representing the lack of T-helper lymphocyte activity, the absence of detectable lymphoproliferative responses to HCV in a minority of individuals with persistent HCV infection, may either relate to antigen-specific CD4 + cells present in the circulation at a frequency below the sensitivity of the assay, or lymphocytes that recognize variable regions of HCV proteins. 185 An alternative explanation is compartmentalization of HCV-specific CD4 + T cells to the liver, as demonstrated in one study. 186 Viral persistence in the face of significant T-helper cell proliferation at the site of viral replication may relate to the observation that, despite 40-80% of liver-infiltrating CD4 + cells expressing activation markers, just 1% of these cells were specific for HCV antigens. 186 However, healthy subjects with lower levels of viraemia exhibit more vigorous proliferative responses to HCV antigens than those with progressive disease, particularly against core protein. 179 This suggests that CD4 + T cells are indeed likely to influence HCV replication in patients with persistent HCV, probably by facilitating other effector mechanisms.
The notion that CD4 + T lymphocytes may either directly or indirectly mediate tissue destruction is supported by the observation that a greater parenchymal concentration of activated CD4 + lymphocytes corresponds with more severe hepatitis. 187, 188 However, in one study, in vitro proliferation of T-helper cells was associated with a lower grade of liver inflammation, suggesting that CD4 + cells may be involved in host protection rather than liver injury. 189 Similarly, higher levels of PBMC proliferation in response to HCV antigens in patients after liver transplantation have been shown to predict less severe histological changes due to HCV recurrence. 190 An association between HLA class II genotype (for example, HLA DRB1*01) 191 and HCV clearance in primary infection, suggests that CD4 + cells help play a critical role in facilitating clearance after HCV exposure. [192] [193] [194] [195] [196] [197] Furthermore, a vigorous CD4 + T-cell proliferative response from PBMC to multiple HCV proteins has been shown to predict disease resolution. 51, 52, 180, [198] [199] [200] [201] Similarly, viral clearance after a course of IFN-α therapy, 181, 182, 202, 203 and combination IFN-α and ribavirin treatment 204 appears to relate to the induction of a vigorous T-helper response. Rather than directly achieving viral clearance, it is likely that T-cell help plays a critical role in facilitating other antiviral immune mechanisms (e.g. CTL) as discussed below.
The CD4 + response to HCV antigens has frequently been shown to persist for up to several decades following viral clearance, without apparent re-exposure to HCV. 58, 201 The response is generally directed at highly conserved immunodominant epitopes within the NS3 and core proteins that bind multiple HLA class II alleles. 205 These features of the host response provide an encouraging backdrop for the development of prophylactic HCV vaccines designed to elicit cellular immune responses.
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Neutralizing antibodies do not prevent hepatitis C infection
During primary HBV infection, the humoral response to envelope antigens contributes to the clearance of circulating virus particles. 15 Similarly, in acute flavivirus infections, such as dengue and yellow fever, viraemia is typically terminated by the appearance of conformation-dependent neutralizing antibodies specific for determinants located on envelope glycoproteins. 11 Clearance of yellow fever virus-infected cells is achieved by antibody-dependent complement-mediated lysis of cells bearing non-structural proteins. 207 208 and exaggerated neurovirulence in yellow fever and Japanese B encephalitis. 209 This phenomenon of antibody-dependent enhancement has not been studied in the context of hepatitis C.
Immunization of chimpanzees with recombinant envelope glycoproteins is associated with the generation of a vigorous humoral response and control of HCV viral replication following a low-dose challenge with the homologous virus (i.e. the strain from which the vaccine was developed), but does not protect against heterologous HCV challenge (i.e. with another HCV isolate). 210 In primary HCV infection, a humoral immune response also typically results in the generation of isolate-specific neutralizing antibodies. 211 These antibodies bind only native and not denatured proteins, suggesting that they recognize conformational epitopes. 212 As well as opsonizing HCV for elimination, antibodies may block viral attachment and impair HCV entry into cells. 213 However, data from chimpanzees and humans suggest that generation of anti-E2 antibodies is not associated with viral clearance. 214, 215 In addition, resolution of primary HCV infection in agammaglobulinaemic children occurs in a similar proportion to the general population. [216] [217] [218] The fact is that most patients with anti-HCV antibodies harbour a replicating virus, are infectious, and have evidence of liver injury. 219 This suggests that antibodies are not protective. However, E2-specific antibodies may be involved in antibody-dependent cellular cytotoxicity (ADCC) against infected host cells. 220 Rather than facilitating viral clearance, ADCC may contribute to hepatocellular damage.
Evolution of the hepatitis C quasispecies may facilitate immune evasion
It has been postulated that the effectiveness of neutralizing antibodies in achieving viral clearance is limited because they have a restricted spectrum of activity against a potentially broad and evolving viral quasispecies. 211 If this is the case, viral persistence in HCV infection may relate to the emergence of neutralization-resistant escape variants present in the quasispecies. 221 Studies of chimpanzees inoculated with RNA transcribed in vitro from a cDNA clone have demonstrated that escape mutants need not be present in the infectious dose to establish persistence. 133 However, in natural infection the selection of pre-existing mutants may occur. 222 The HVR1 of E2 has been shown to be a critical target for neutralizing antibodies. 213, 223 Emergence of variants in vivo with mutations in this region may lead to a loss of antibody recognition of HVR1 epitopes and result in persistent HCV infection. [224] [225] [226] [227] Resolution of primary HCV infection has been associated with stasis of the quasispecies, and, conversely, progression to persistent infection has been associated with sequence changes within the HVR1. 228 However, other factors are likely to be involved in viral persistence as demonstrated by the observation that HCV can cause persistent infection in chimpanzees in the absence of mutation events in the HVR1. 229 Evolution of the quasispecies may provide the basis of establishment of persistence by selection for mutations in other parts of the HCV genome, such as alternative envelope and non-structural regions, 133 which may be the targets for other host response mechanisms as outlined below. Indeed it has been argued that the primary failure in subjects who develop persistent HCV infection is a poor cellular immune response and that quasispecies evolution is the result of persistence rather than the cause. In this model, a lack of T-cell help by CD4 + cells leads to poor early viral control by CTL, restricted generation of antibody specificities, high selective pressure and immune escape. 230 Alternatively, the observation that anti-HCV antibodies are not protective may simply relate to the timing of the generation of the humoral immune response in primary infection. Hepatitis C virus clearance has been associated with early antibody generation. 231 Although there is no evidence in HCV infection, a delay in the production of neutralizing antibodies, and subsequent persistent infection, may relate to the appearance of HCV-specific CTL and the selective destruction of antigen-specific B cells expressing viral peptides in association with MHC class I. 232, 233 Is the cellular immune response to hepatitis C similar to that seen in hepatitis B?
In hepatitis B, in conjunction with an MHC class II-restricted CD4 + T-helper response, virally encoded peptides synthesized within infected host cells and presented in association with class I molecules, induce a CD8 + CTL response. 177 Polyclonal MHC class I-and II-restricted responses to structural and non-structural proteins are crucial for elimination of HBVinfected cells. In vitro studies suggest that the cellular immune response is vigorous and encompasses a broad range of epitopes in acutely infected patients who clear HBV, while the response is more narrowly focused in the 5% of adults who develop persistent infection. [234] [235] [236] [237] In contrast to adults, approximately 90% of neonates develop persistent HBV infection following vertical transmission. 15, 238 Neonatal tolerance to maternally derived circulating HBV e antigen may facilitate persistent HBV infection after perinatal exposure. 239 However, vertical transmission of HBV also results in milder hepatitis, suggesting that the immune response may contribute to liver damage as well as having a role in host protection. 15 This is supported by the observation that immunodeficient individuals have a higher rate of persistent HBV, but milder liver disease. 240 Consistent with this notion of immunologically mediated hepatocyte injury is the observation that both spontaneous clearance and acute exacerbations in patients with chronic HBV hepatitis are associated with stronger CTL activity. The direct hepatocytolytic effect of HBV-specific CTL in vivo has been demonstrated by the development of dose-dependant severe necro-inflammatory liver disease following adoptive transfer of HBV-specific CD8 + T-cell clones into transgenic mice expressing HBV antigens. 241 Experiments using cytokine-specific neutralizing antibodies have demonstrated that in addition to direct cell lysis, CTL may inhibit intracellular HBV replication and cause liver damage via non-cytolytic mechanisms such as the secretion of IFN-γ and TNF-α. 242 Viral clearance without hepatocyte destruction has been demonstrated in chimpanzees with acute HBV infection. 243 As the majority of hepatocytes become infected in acute HBV, antiviral cytokines may be important in achieving viral clearance, while avoiding massive hepatocyte necrosis and fulminant hepatic failure, thereby ensuring host survival. 244 Noncytopathic clearance of hepatotropic pathogens also occurs in murine cytomegalovirus (CMV) and lymphocytic choriomeningitis virus (LCMV) infection. 245, 246 Cytotoxic T cells specific for non-structural proteins presented in association with MHC class I may also contribute to the termination of flavivirus infections, with Kunjin and West Nile virus. 247 Flaviviruses can upregulate MHC class I expression on infected host cells, thereby augmenting CTL-mediated cell lysis.
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Different methods used to study cytotoxic T lymphocytes in hepatitis C have produced varied results
Several groups have studied HCV-specific CTL responses in peripheral blood and liver from HCV-infected patients and chimpanzees. Two assay strategies have been employed. The first has concentrated on the peripheral blood CTL response after in vitro HCV-peptide stimulation to expand the HCVspecific effector population. [249] [250] [251] HLA-A2-restricted CTL activity in peripheral blood has been studied extensively because of the ease with which peripheral blood T cells are sampled and because of the high frequency of the HLA-A2 haplotype. The HLA-B44-restricted HCV-specific CTL response has been studied in Japanese patients because of an association with persistent HCV infection. 249 The second strategy has sought to characterize the intrahepatic CTL response after T-cell expansion using non-antigen specific proliferative stimuli, such as anti-CD3 antibodies. 252, 253 In persistent HBV infection, HBV-specific CTL are generally undetectable in peripheral blood. By contrast, at least one HLA-A2-restricted CTL epitope (of 10 studied) was recognized by expanded PBMC in 97% of patients with persistent HCV infection. 254 In general, the anti-HCV response was multispecific, with an average of four CTL epitopes being recognized in each patient. These CTL epitopes were located both in the structural and non-structural proteins of the virus. 171 Given that the major site of HCV replication is believed to be the hepatocyte, and that chronic hepatitis due to HCV is characterized by a CD8 + T-cell infiltrate, it is not surprising that HCV-specific CTL are sufficiently abundant in the liver that they can be detected after antigen-nonspecific expansion through the T-cell receptor complex. 255 This method avoids virus-specific stimulation so that cells with a particular specificity are not selectively expanded. Using this technique, intrahepatic HCV-specific CTL activity can be detected in approximately 50% of cases. 256, 257 Intrahepatic CTL responses directed at multiple epitopes, including up to five structural and non-structural viral proteins, were demonstrated in patients with persistent HCV infection. 258 Many of the epitopes identified after non-specific stimulation have been shown to conform to predicted MHC binding motifs, however, CTL epitopes recognized by both intrahepatic and peripheral blood effectors have been identified for which no published motif exists, suggesting that predicted binding motifs are not always reliable for identifying immunodominant determinants. 258, 259 The degree to which the peripheral blood CTL response detected after antigen-specific stimulation reflects the intrahepatic response is unknown. Our group has investigated intrahepatic and peripheral blood CTL activity in patients with persistent hepatitis C after in vitro expansion using autologous cells infected with recombinant vaccinia viruses encoding HCV genes. 260 A broad and vigorous HCV-specific CTL response was demonstrated in the majority of patients, with substantially higher CTL activity evident with liverderived mononuclear cells than in peripheral blood (Fig. 4) . This suggests that HCV-specific CTL are concentrated at the site of maximal viral replication and tissue injury.
Cytotoxic T lymphocytes may control viral replication in subjects with persistent hepatitis C infection
The mechanism by which HCV persists despite the presence of a sustained, multispecific CTL response is not clear. Such a finding is particularly surprising considering that MHC class I, intercellular adhesion molecules and Fas antigen are all upregulated in the liver during HCV infection, and should facilitate cell binding, antigen recognition, and hepatocyte lysis. 261, 262 Although there is no evidence in HCV, one explanation may be that infected hepatocytes are induced to express Fas-ligand and may protect themselves against CTL-mediated injury by destroying virus-specific CTL via the same pathway that CTL use to kill their targets. 263, 264 Cytotoxic T lymphocytes may play a role in controlling viral replication in patients with persistent HCV infection. Attempts to correlate CTL activity with viral load have produced conflicting results. Our experiments suggest that a vigorous intrahepatic CTL response is associated with lower levels of viraemia. 260 In one other study, the presence of an HCV-specific CTL response in liver-infiltrating lymphocytes was also associated with lower viral load. 256 However, other studies have been unable to confirm this observation. 257 An analysis of peripheral blood responses demonstrated no correlation between HCV-specific CTL precursor frequencies and viral load. 171 However, in a related study the overall combined peripheral blood CTL response against a panel of epitopes was higher in patients whose HCV RNA level was below the threshold of detection, 254 suggesting that HCVspecific CTL may be able to exert some control over viral replication, but not enough to terminate infection. A similar inverse relationship has been demonstrated between viral load and the HLA-B44-restricted peripheral blood CTL response to HCV core antigens. This may suggest that similar to HBV, CTL may contribute to the liver damage in patients with HCV. While some investigators have failed to show any distinct cellular infiltrate at the site of antigen-positive hepatocytes, 266 others have demonstrated CD8
+ cells in contact with apoptotic bodies and hepatocytes containing HCV antigens. 261 In addition, studies have demonstrated a correlation between the number of lobular CD8 + cells, serum transaminase levels and the degree of histological inflammation. 265 However, correlations between functional assessments of HCV-specific CTL activity in vitro from persistently infected individuals with liver injury have produced conflicting results. The presence of liverderived CTL activity was associated with a higher hepatic Figure 4 Intrahepatic and peripheral blood hepatitis C virus (HCV)-specific CTL responses and natural killer activity expanded from a patient with chronic HCV infection. Liver and peripheral blood mononuclear cells were expanded for six days in vitro using autologous cells infected with recombinant vaccinia virus constructs encoding HCV genomic regions (HCV genotype 1a core to NS2 (ᮀ) and genotype 1a NS2 to NS5 ( )). 88 Autologous B lymphoblastoid cell lines were infected with the HCV-vaccinia virus constructs and vaccinia virus expressing the Escherichia coli b-galactose gene (vv-Lac, control ()). Target cell lysis was assessed in a 51 Cr-release assay. Natural killer activity was assessed against K562 targets ( ). Intrahepatic lymphocytes displayed significant HCV-specific CTL activity against both genomic regions. Significantly less HCV-CTL was seen from peripheral blood effectors. Natural killer activity was high in blood and absent in liver.
necro-inflammatory score in one study. 256 In contrast, analyses of peripheral blood HCV-specific CTL responsiveness demonstrated an inverse correlation with serum transaminase levels. 254, 267 This may be because HCV-specific CD8 + cells home to the liver as intrahepatic viral load increases and, therefore, are less frequently detected in the peripheral circulation in the context of more severe hepatitis. At odds with the hypothesis that CTL are directly responsible for liver injury in chronic HCV hepatitis is the recent report that only 1-2% of the total CD8 + cells infiltrating the liver, as detected by flow cytometric analysis of T cells stained with biotinylated MHC class I-peptide tetrameric complexes (tetramers), were HCV-specific. 268 Similarly in HBV infection, tetramer staining has demonstrated that the bulk of the intrahepatic CD8 + cells in patients with severe hepatic inflammation are not specific for viral antigens. 269 However, these studies only identified virus-specific CD8 + cells for which tetramers were available. Nevertheless, non-specific cytotoxic cells recruited by IFN-γ may contribute to liver damage in chronic viral hepatitis. 270 Considering the close interplay between CD4 + help and CTL function, it has been postulated that deficient CD4 + T-helper function, in association with ongoing CTL activity and IFN-γ production, may be responsible for maintaining the low-grade hepatic inflammation and injury associated with persistent viraemia. A comprehensive evaluation of intrahepatic and peripheral blood cellular immunity in conjunction with measurement of viral load and assessment of hepatic necro-inflammatory activity may help clarify the situation.
Hepatitis C virus clearance in primary infection may depend on the vigour, breadth and quality of the early host CTL response
Immunity in self-limited HCV infection has been difficult to define as the illness is largely asymptomatic, and thus patients rarely present to medical attention with primary infection. Despite this, the role of cellular immune factors in viral clearance during primary HCV infection has recently been addressed using techniques such as enzyme-linked immunospot (ELISPOT) assessment of IFN-γ production, tetramer and intracellular cytokine staining. In two experimentally infected chimpanzees, a vigorous, multispecific, intrahepatic CTL response, which persisted for over 1 year, and a limited antibody response were associated with viral clearance. 271 These data must be interpreted cautiously given that in contrast to humans, only a minority of chimpanzees develop persistent HCV infection. However, a follow-up study of women who cleared HCV after exposure to contaminated human Rhesus immunoglobulin similarly demonstrated that while circulating HCV-specific antibodies were undetectable in 42% of cases 18-20 years after exposure, memory HCV-specific helper and cytotoxic T-cell responses persisted in 79% and 92%, respectively. 58 Other investigators have confirmed that greater numbers of HCV-specific CD8 + T cells are found in patients with self-limited primary HCV infection, 272, 273 that an early, broadly directed response is critical, 274 and that T-helper and CTL responses persist after resolution of clinical hepatitis. 200 This has not been a universal finding with one report of comparable numbers of HCV peptide-specific IFN-γ producing cells in the peripheral blood of persistently infected patients and recovered subjects. 275 It may be that the responses in the liver differ from activity in blood. In line with this, early homing of HCVspecific CD4 + and CD8 + cells from blood to liver has been shown to be critical in chimpanzees that clear HCV infection. 276 The detection of HCV-specific T cells in anti-HCV negative blood donors, 251 HCV-exposed seronegative healthcare workers, 277 spouses 278 and healthy family members 279 of persistently HCV-infected patients raises the notion that a cellular immune response may remain after the loss of anti-HCV antibodies, or persist in people who never generate a significant antibody response. It is possible that cellular immunity persists due to retained antigen, or even plausibly low-level viral replication in the liver of clinically recovered patients. 58, 280 Alternatively, the response may reflect prior sensitization to non-HCV antigens. 281 The ability of HCV to evade cellular immunity may relate to the observation that such responses, similar to humoral responses, have a viral-isolate specific spectrum of activity that may be ineffective against divergent strains present in the HCV quasispecies. The emergence of CTL epitope variants early in the course of primary infection may contribute to HCV persistence. 282 Following primary infection in a chimpanzee that subsequently developed chronic hepatitis, liverinfiltrating CTL were identified that recognized an epitope in NS3, however, mutation at a single amino acid within the epitope resulted in the loss of CTL recognition. 283 Mutant epitopes that emerge in this context may function as CTL antagonists and prevent T-cell recognition of the wild-type epitope. 282, [284] [285] [286] However, because the HCV-specific CTL response is generally multispecific, the mere loss of a single epitope should not provide sufficient survival advantage to the mutant. In addition, other flaviviruses have the same error-prone RNA-dependant RNA polymerase, which is responsible for the quasispecies nature of HCV, and yet rarely establish persistent infection. 287 It has been argued that the selection of escape mutants occurs in the setting of preexisting persistent infection, that is, viral persistence leads to the selection of escape variants, not the converse. 288 The extent to which quasispecies complexity contributes to, or is a consequence of, persistent HCV infection remains to be determined.
Early vaccine strategies provide promise for the control of hepatitis C
It is clear that the quasispecies nature of HCV and the multiple prevalent genotypes pose a major challenge for the development of a protective vaccine. 289 It is generally believed that an effective HCV vaccine would have to induce a vigorous, multispecific cellular immune response in order to eradicate HCV before the selection of escape mutants. Identification of conserved CTL epitopes restricted by multiple HLA alleles may facilitate the design of a vaccine that is immunogenic in the general population. 267 A priming immunization with naked HCV-E2 DNA followed by a booster immunization with recombinant E2 protein (the so-called 'prime-boost' regimen) induced CTL activity and protected mice against tumour-expressing E2. 290 Two chimpanzees vaccinated with HCV-E2 DNA also generated strong CTL responses, and after a viral challenge both resolved primary HCV infection early. 291 A DNA prime and canarypox-HCV boost strategy using a polycistronic construct from the HCV core to the NS3 region has been shown to broaden the range of structural and non-structural epitopes targeted by HCV-specific CTL and IFN-γ-producing cells in immunized mice.
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Anti-viral cytokines regulate the immune response to hepatitis C
The observed pattern of a vigorous CTL response and relatively weaker humoral response predicting disease resolution suggests that HCV persistence also relates to the pattern of cytokine release. 189 In primary HCV infection, viral clearance is more likely in patients displaying a T-helper 1 profile, 51, 58, 184, 198, 199, 293 while T-helper type 2 cytokines may downregulate HCV-specific cellular immunity and promote viral persistence. 294 Similarly, while higher serum IL-10 levels correlate with a poor response to treatment, 295 a sustained treatment response has been associated with decreased IL-4 and IL-10.
204,296 Activated HCV-specific CTL early in primary infection may be unable to secrete IFN-γ, representing a 'stunned' phenotype. 200, 297 Recovery from this may be important in affecting viral clearance. Hepatitis C virus core protein has been shown to directly downregulate IFN-γ and IL-2 production in mice. 298 A predominance of type 2 cytokines, and a lack of IL-2 production by peripheral blood T-helper cells proliferating in response to NS3 has been demonstrated in persistent HCV infection. 299 A reservoir of HCV may thereby be maintained in peripheral blood that continually reinfects the liver. 300 Modification of cytokine responses by immune mediators other than IFN-α, for example, to promote a shift to T-helper type 1 predominance in response to IFN-β, may have future therapeutic applications. 301 Despite a lower proportion of infected hepatocytes than in HBV, the number of HCV-infected cells is still so large that the CTL response is not likely to be able to eradicate HCV, while avoiding massive hepatocyte necrosis simply by killing infected cells. 302 Persistence may, therefore, simply relate to a relative insensitivity of HCV to antiviral cytokines such as TNF-α and IFN-γ. 275, 303 However, HCV core protein has been shown to bind the cytoplasmic domain of TNF receptor 1 and enhance, rather than prevent, TNF-induced apoptosis. 304 Other cytokines are also likely to play a role in immunemediated liver damage. 305 The levels of IL-2 and IFN-γ have been shown to correlate with the degree of hepatic inflammation and fibrosis. 306, 307 Liver damage may extend from virally infected target cells to uninfected bystander hepatocytes via the release of other apoptotic mediators, such as Fas-ligand (Fas-L) from activated CTL. 258, 308 Little is known about the role of innate immunity in hepatitis C Uninfected human liver contains a high proportion of natural killer (NK) cells, 309 and recently liver has also been shown to contain a significant population of cells with both NK-cell and T-cell phenotypic and functional characteristics, the natural T (NT) cells. 310 These cells feature heavily biased T-cell receptor (TCR) gene usage, CD1d restriction and high levels of cytokine production, particularly IL-4 and IFN-γ. 311 In several murine models of infection, liver NT cells appear to play a key role in the host response. 311 Thus, both NK and NT cells may have significant bearing on the immune response to hepatotropic pathogens such as HCV. Early NK-cell expansion, prior to the proliferation of CD4 + and CD8 + virus-specific cells, has been shown to control viral replication in murine models of viral hepatitis, such as LCMV. 312 The high rate of HCV persistence following primary infection may plausibly relate to the observation that patients who develop persistent HCV infection have impaired NK activity, 313 and few intrahepatic NK cells. 314 Studies of this cell type in the liver of humans or chimpanzees with primary HCV infection are yet to be performed to better inform this debate. Similarly, virtually no data exists examining the potential role of NT cells in initiation or propagation of the host response to HCV.
Similar to CTL it has been suggested that lymphocytes typically found in innate immune responses may play a role in producing chronic liver damage in HCV infection. Migration of NK and NT cells from blood to liver has been demonstrated in patients with persistent HCV infection. 315 However, flow cytometry and in situ immunophenotyping of intrahepatic cytotoxic cells has demonstrated that NK and NT cells are not expanded in number in patients with chronic HCV hepatitis, thus suggesting that these cells are unlikely to play a major role in hepatocellular injury. 265, 316 Hepatitis C may use liver tolerance to promote its own persistence
The relatively low requirement for immunosuppression to avoid organ rejection after allogeneic liver transplantation suggests that the liver may be a site for the induction of peripheral tolerance. 317 This predisposition towards immune tolerance may relate to the observation that the liver is exposed to numerous harmless foreign antigens, including food and bacteria, from the intestine. 318 Oral tolerance appears to involve both T-cell inactivation and deletion. 319 The hepatotropic nature of HCV may facilitate the induction of tolerance and viral persistence. Activated HCV-specific T cells may be 'trapped' in the liver after antigen recognition on hepatocytes. Cells of the innate immune system may mediate apoptosis of activated cells, thereby terminating their antiviral function. 315, 318 In transgenic mice, enhanced apoptosis has been shown to be induced in activated T cells exposed to hepatocytes expressing HCV structural proteins. 320 Alternatively, tolerance induction may relate to the observation that hepatocytes lack expression of costimulatory molecules, such as B7, and recognition of peptide in association with MHC class II by CD4 + cells may result in antigen-specific non-responsiveness.
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A number of viral factors may facilitate immune evasion by hepatitis C Hepatitis C virus proteins, such as core, 298 ,321 E2 322 and NS5, 323 may interfere with the immune response, for example, by inhibition of the interferon-induced protein kinase PKR or binding to the gC1q complement receptor. 324 Persistence may also be based on the kinetics of infection relative to the induction of immunity. During the early stages of infection a high rate of production of HCV virions may simply exceed the capacity of the immune response. 91 Immunological tolerance may subsequently develop due to 'exhaustion' of the response in persistently viraemic patients. 325 Viral persistence may also occur in the face of low levels of HCV replication, small doses of antigen, suboptimal T-cell activation, impaired proliferation and poor IL-2 production. 326 Suppression of viral gene expression by a suboptimal immune response may facilitate persistent infection by reducing viral antigen expression so that infected cells escape immune recognition. 288 Another potential method of immune evasion is replication in an immunologically privileged extra-hepatic site. For example, there is evidence for infection of pluripotent haematopoietic CD34 + stem cells. 327 Lymphoid cells may thereby act as a reservoir of the virus that continually reinfects the liver. As discussed earlier, due to variations in the HVR1 potentially altering the tropism of different components of the HCV quasispecies, and the observation that progression to persistent infection has been associated with evolution of the HVR1, 228 viral persistence may relate to mutations in the HVR1 facilitating HCV sequestration in immunologically privileged sites. In addition, infection of cells of the immune system, for example, dendritic cells, 328 may impair their function. Consistent with this is the observation that dendritic cells recovered from HCV-infected patients display impaired allostimulatory activity.
329
Hepatitis C virus may be directly cytopathic
In general in flavivirus infection, disease pathogenesis relates primarily to a direct cytocidal effect of the virus on host cells. Severe disease is characterized by high levels of viral replication, rapid accumulation of antigen and an aggressive inflammatory response. 11 The observation that the degree of liver damage in HCV-associated fulminant hepatic failure parallels the level of viral replication supports the notion that HCV may directly contribute to hepatocyte injury. 330 In addition, highly viraemic liver transplant patients on immunosuppression may suffer cholestatic liver disease attributed to a direct cytopathic effect of HCV. 331 The more typical situation in the immunocompetent host with established infection is controversial. Reports in patients with chronic HCV hepatitis have suggested a correlation between more severe histological changes and higher serum [332] [333] [334] and intrahepatic 335, 336 HCV RNA levels, and a greater proportion of hepatocytes carrying negative-strand replicative intermediates. 113 Against the argument for HCV having a direct cytopathic role are other studies that demonstrate no correlation between either intrahepatic RNA levels or the proportion of infected hepatocytes and necro-inflammatory activity. 109, [337] [338] [339] [340] [341] In addition, significant hepatocellular death is not seen in transgenic mice that express HCV core or E2 in the liver, although steatosis (which is also commonly observed in human infection) is apparently induced. 342 It may be that the process of replication, rather than simply the presence of individual HCV proteins, induces HCV-associated cytopathic damage. 113 However, it is well recognized that HCV replication can occur in patients without significant liver damage. 343 The role of viral complexity as a pathogenic mechanism in hepatocellular injury has also been investigated. The degree of diversity of the HCV quasispecies has been shown to correlate with disease severity, such that the within-patient variation in nucleotide sequence increases with the severity of liver disease. 138, [344] [345] [346] [347] However, this has not been a universal finding and may simply relate to a longer duration of infection. [348] [349] [350] Longitudinal analysis of HCV quasispecies after primary infection has demonstrated that the complexity of the quasispecies may predict the subsequent course of HCV. A decrease in diversity is seen in patients that clear primary infection, and a dramatic increase in patients with rapidly progressive chronic hepatitis. 228, 289 In contrast, greater rates of HCV quasispecies diversification are associated with less severe disease in immunocompromised patients after liver transplantation 351 . The different methods used to describe quasispecies diversity may explain such disparate findings.
Conclusion
Despite a decade of research since the discovery of HCV as an important agent responsible for chronic viral hepatitis, much remains to be defined regarding pathogenesis. Considerable efforts are being directed towards the development of an in vitro system to support viral propagation. Such a system will assist in defining the role of various viral proteins in translation, replication and critical virus-host cell interactions, for example, the means of HCV entry into hepatocytes. With regard to disease pathogenesis, the conclusions to date are largely based on studies of small numbers of chimpanzees, or, because of the difficulties in recruiting patients with primary HCV infection, observations have predominantly been made in subjects followed up long after HCV clearance, or in those who have persistent infection. Thus, key information regarding the evolution of the host response and viral dynamics early after infection is lacking. An additional consideration is the difficulty in sampling human hepatic tissue. Anti-viral immunity in the liver appears likely to differ significantly from the immune response observed in peripheral blood. A prospective and systematic evaluation of immunity, in conjunction with the assessment of viral replication and quasispecies, in a number of patients with primary HCV infection will assist in defining the nature of protective immunity. A better understanding of these immunological correlates of viral clearance will then facilitate immunotherapeutic and vaccine strategies.
